Barrington Research Reaffirms “Outperform” Rating for Merit Medical Systems (NASDAQ:MMSI)

Barrington Research restated their outperform rating on shares of Merit Medical Systems (NASDAQ:MMSI) in a report released on Monday,Benzinga reports. Barrington Research currently has a $114.00 price target on the medical instruments supplier’s stock. Barrington Research also issued estimates for Merit Medical Systems’ FY2026 earnings at $4.28 EPS.

Several other analysts have also weighed in on MMSI. Robert W. Baird boosted their target price on shares of Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $109.00 price objective on shares of Merit Medical Systems in a research report on Thursday, October 31st. StockNews.com cut shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Bank of America upped their target price on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a report on Monday, September 16th. Finally, Wells Fargo & Company raised Merit Medical Systems from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $103.00 to $120.00 in a report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $105.60.

Merit Medical Systems Stock Performance

Shares of MMSI stock opened at $98.08 on Monday. The stock has a market capitalization of $5.72 billion, a price-to-earnings ratio of 48.08, a PEG ratio of 2.55 and a beta of 0.84. Merit Medical Systems has a one year low of $70.70 and a one year high of $108.07. The company’s 50-day simple moving average is $100.84 and its 200-day simple moving average is $94.15. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company had revenue of $339.85 million for the quarter, compared to the consensus estimate of $334.60 million. During the same quarter last year, the business posted $0.75 EPS. Merit Medical Systems’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities analysts anticipate that Merit Medical Systems will post 3.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 29,646 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the transaction, the chief financial officer now owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. This trade represents a 64.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director F. Ann Millner sold 12,500 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the sale, the director now owns 32,391 shares in the company, valued at $3,289,306.05. This trade represents a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tidal Investments LLC boosted its position in shares of Merit Medical Systems by 1.0% during the 3rd quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock valued at $1,028,000 after purchasing an additional 104 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Merit Medical Systems by 2.9% in the 2nd quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 118 shares during the period. Xponance Inc. increased its stake in Merit Medical Systems by 4.9% in the 2nd quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock worth $311,000 after purchasing an additional 170 shares in the last quarter. Glenmede Trust Co. NA raised its holdings in Merit Medical Systems by 0.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock worth $2,830,000 after buying an additional 170 shares during the period. Finally, Captrust Financial Advisors lifted its stake in Merit Medical Systems by 2.6% during the third quarter. Captrust Financial Advisors now owns 7,440 shares of the medical instruments supplier’s stock valued at $735,000 after buying an additional 187 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.